Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 205,911 shares at $0.85 ($155K) on 2026-04-27, disclosed to the SEC on 2026-04-29.
Scheduled sale ($155k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.85 | 53,940 | $46K | 29.7% |
| 2 | $0.73 | 95,412 | $70K | 45.1% |
| 3 | $0.69 | 56,559 | $39K | 25.3% |
| Total | $0.75 avg | 205,911 | $155K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |